<DOC>
	<DOC>NCT00409526</DOC>
	<brief_summary>Inhaled Iloprost will be administered to near term infants with Persistent Pulmonary Hypertension of the Newborn in two different doses in order to test safety and efficacy in reducing pulmonary artery pressure.</brief_summary>
	<brief_title>Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.</brief_title>
	<detailed_description>Infants eligible for the study will be divided into two arms according to oxygenation index: Infants in arm A (OI &lt;20) will receive nebulized Iloprost in a lower dose (50 ng/kg/min) for one hour, and a higher dose (100 ng/kg/min) for another hour. Infants in arm B (OI&gt;20) will receive NO, and in addition will receive nebulized Iloprost in a lower dose for one hour and a higher dose for another hour.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Nearterm infants (&gt;34 gestational age) with evidence of persistent pulmonary hypertension and severe hypoxia(PaO2&lt;100 mmHg with mechanical ventilation with FiO2=100%). Major congenital malformation Congenital diaphragmatic hernia Structural cardiac anomalies Hydrops fetalis Pulmonary hemorrhage Severe perinatal depression Patients on high frequency oscillation ventilator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Days</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Iloprost</keyword>
	<keyword>PPHN</keyword>
	<keyword>Newborn</keyword>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Term</keyword>
	<keyword>Persistent Pulmonary Hypertension of the Newborn</keyword>
</DOC>